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We should first try to define systemic lupus 
erythematosus (SLE). Table 1 lists criteria proposed 
by a committee of the American Rheumatism Asso-
ciation ( 1). If four of these 14 major criteria are 
positive, then there should be about 98% specificity 
for SLE. There are clearly many facets to this dis-
order. Let us consider mechanisms that might ac-
count for a multisystem disease such as this. 
A good model is that of experimental serum 
sickness. Though Germuth (2) provided much of 
the renewed impetus to study serum sickness in the 
'SO's, it is Dixon (3) who has fully explored the 
variables of immune complexes and disease. 
When a rabbit is given a single intravenous 
injection of bovine serum albumin (BSA) labelled 
with 1811, one notes disappearance of the BSA in 
serum over a period of about 13 days. First there 
is a rapid fall, then an equilibrium dev~lops; and 
then suddenly there is total disappearance of the 
injected BSA. Coincident with the rapid disappear-
ance of BSA, one can measure antigen-antibody 
complexes. Finally, free antibody to BSA is detected. 
During the period when these immune complexes are 
found, the rabbits develop heart disease, arthritis, 
nephritis, and other manifestations. It is a self-
limited disease, however, and when free antibody 
is found the disease clears up. Hemolytic comple-
ment (C) has been measured also; with the appear-
ance of immune complexes, the C level falls, later 
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returning to normal. This then is the model of 
experimental serum sickness in the rabbit; what 
about immune complexes in man? 
We are postulating that many manifestations 
of SLE probably result from deposition of circulating 
immune complexes. Numerous data are now avail-
able which would support this concept. What can 
we now do to find these eomplexes and characterize 
them? If we can show what is in these complexes, 
we should know something more about pathogenesis. 
Table 2 lists some of the methods that are 
available today. These methods are mostly limited 
to research laboratories. I have listed these methods 
as either analytical or preparative. Cryoprecipitation 
is both analytical and preparative; furthermore, 
cryoprecipitates are easily measured since all one 
needs is a refrigerator and a centrifuge. Recent 
studies by Mcintosh et al. ( 4) suggest that cryo-
precipitates correlate well with immune complex 
formation in rabbits; evidence in man is not as 
convincing since it is difficult to recover a specific 
pathogenetic antigen in SLE cryoprecipitates. 
Clq precipitation was first described by Agnello 
et al. (5); here one utilizes purified Clq to pre-
cipitate with serum factors in double diffusion 
systems. Rheumatoid factor (RF) can be used in 
the same way. Efforts in our lab are now being 
directed toward an analysis of the characteristics of 
Clq reactive factors. It is of interest that Clq and RF 
seem to detect different substances in serum. Passive 
agglutination of RF-coated cells is another method 
which detects complexes, as is complement fixation 
(which is a way of interpreting "anticomplementary 
serum"). Recent work in England has shown com-
plement fixation and Clq precipitins not only in 
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TABLE 1 
PRELIMINARY CRITERIA FOR CLASSIFICATION OF SLE 
!. Facial Erythema (Butterfly Rash) 
2. Discoid Lupus 
3. Raynaud's Phenomenon 
4. Alopecia 
5. Photosensitivity 
6. Oral or Nasopharyngeal Ulceration 
7. Arthritis without Deformity. [One or more peripheral 
joints involved with any of the following in the absence 
of deformity: a) Pain on motion, b) Tenderness, c) 
Effusion or periarticular soft tissue swelling.] 
8. LE Cells 
9. Chronic False-Positive STS 
10. Profuse Proteinuria 
11. Cellular Casts 
12. One or both of the following: a) Pleuritis, b) Pericarditis 
13. One or both of the following: a) Psychosis, b) 
Convulsions 
14. One or more of the following: a) Hemolytic anemia, b) 
Leukopenia c) Thrombocytopenia 
SLE serum but in sera from patients with dermatitis 
herpetiformis, ulcerative colitis, regional enteritis, 
and coeliac disease ( 6, 7). Lymphocyte inhibition 
is another technique recently reported: B cells, 
which kill sensitized tumor cells, are inhibited by 
serum containing aggregates or immune complexes 
( 8). Platelets can also be agglutinated by com-
plexes. 
Cryoprecipitation is, at the same time, a pre-
parative method. Likewise Clq can be linked to 
Sepharose® columns through cyanogen bromide to 
facilitate removal of Clq precipitins from serum for 
analysis (9). Hopefully, the immune complexes and/ 
or aggregates will stick and everything else will wash 
through; then the bound material can be eluted off 
TABLE2 
DETECTION OF CIRCULATING IMMUNE COMPLEXES AND / OR 
AGGREGATES 
Analytical 
Cryoprecipitation 
Clq detection in agarose gel 
RF detection in agarose gel 
or reverse hemagglutina-
tion 
Complement fixation 
Lymphocyte inhibition 
Platelet agglutination 
Preparative 
Cryoprecipitation 
Cl q precipitation 
Adsorption to columns of 
insoluble Clq 
Isolation by column 
chromatography 
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with salt and the residue analyzed. Serum can also 
be run directly through agarose columns with ex-
clusion of large molecular weight materials. In sum-
mary, the main point here is that many methods are 
being developed to find and characterize aggregates 
and complexes; the simplest method is probably 
cryoprecipitation. 
Figure 1 shows various factors which we mea-
sured longitudinally in one SLE patient several years 
ago. The relationship between serum cryoglobulins 
and C levels is particularly noteworthy (our normal 
range for serum hemolytic complement is 34-48 
CH50 units/ ml) and one can clearly see the re-
ciprocal relationship between C and cryoglobulin 
during the time span. This negative correlation is 
not always seen but usually is. 
Figure 2 shows findings in another patient. 
Here the C level is first found in the normal range 
at a time when no cryoglobulins are seen. As the 
cryoglobulins appear, C levels begin to fall. It should 
also be noted that the antinuclear factor (ANF) 
remained fairly constant during this time period, 
though no titers were done. It has been our experi-
ence that when we use a 1 :4 dilution of serum for 
the ANF test, little change in ANF can be noted 
between acute exacerbations and remissions of SLE. 
With prolonged remission, however, the staining may 
become less intense, though the ANF rarely dis-
appears entirely in SLE patients. RF titers (usually 
low titers, when found) also tend to remain quite 
constant in SLE patients, though RF was not found 
in either of the patients shown in these figures. 
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Fig. I-Laboratory findings in a patient with SLE over a 
16-month period. The reciprocal relationship between C 
and cryoglobulins is noteworthy. Antinuclear factor and 
proteinuria are relatively stable during this time. 
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Fig. 2-Laboratory findings in another patient with SLE. 
Very little proteinuria is noted even when the C level is 
low and large amounts of cryoglobulin are found. 
Clq precipitins have been found primarily in 
SLE patients with low serum C levels according tb 
one report (10) . In a group of 30 SLE patients with 
low C levels, 23 were positive for Clq precipitins; 
of those SLE patients who had normal C levels none 
were positive for Clq precipitins. A few p~tients 
with miscellaneous diseases were positive ( 6/ 150) . 
Table 3 shows our results: Of 908 total sera 
tested for Cl q precipitins, 19 % were positive. (These 
sera came from patients who had a variety of diseases 
and were mainly suspected of having a connective 
tissue disease or vasculitis.) Of the lupus sera, 15 % 
were positive and of the lupus patients, 43 % were 
positive on at least one occasion. Sera from patients 
with other diseases were positive 27 % of the time, 
the 28 % positivity of nonlupus patients reflecting 
the fact that many of these patients were only 
studied by this technique on one occasion . Of par-
ticular note is the finding of Clq precipitins in other 
diseases besides SLE-a finding supported by other 
investigators ( 6, 7, 10) . 
TABLE 3 
Clq PRECIPITATION 
Total #Positive 3 Positive 
Total Sera 908 174 19 
Lupus Sera 601 90 15 
Lupus patients 95 41 43 
Other Sera 307 84 27 
Other patients 216 61 28 
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TABLE 4 
Clq PRECIPITINS VS. CRYOGLOBULINS 
# Positive 3 Positive 
Total Sera (106) 16 15 
Lupus Sera (74) 11 15 
Other Sera (32) 5 16 
Cryoglobulins (106) 0 0 
Cryo. Supernatants (106) 24 23 
Lupus (74) 18 24 
Other Sera (32) 6 19 
Results of the Clq precipitin test as it relates 
to sera with cryoglobulins ate shown in Table 4. 
One notes that of the 160 sera tested here, 16 were 
positive for Clq precipitins; aild of these 16 sera, 
11 were SLE seta and 5 were other disease sera. 
Only some of these sera had cryoglobulins, but we 
treated them all as if they did-that is, they were all 
centrifuged after 48 hours in the cold and the super-
natant transferred to another tube for testing against 
Clq. The cryoprecipitates, whether visible or not, 
were resolubilized at a ten-fold concentration and 
also retested against Clq. No cryoprecipitates showed 
a precipitin line, suggesting that 1 ) there was not 
enough material, 2) the material did not react with 
Clq, or 3) that the cryoprecipitate was already satu-
rated with bound Clq. Of more importance, how-
ever, was the finding that of the 106 supernatants, 
24 (instead of 16) were now positive. Ali of the 
16 sera which were positive originally remained pos-
itive when the supernatant was checked and eight 
sera which were originally thought to be negative 
were now positive after removal of any cryoprecipi-
tates. These studies have suggested to us that cryo-
globulins have properties, at least in part, distinctive 
from Clq precipitins. Possibly the cooling and cen-
trifugation of certain sera lead to aggregation of small 
complexes that do not spin down as cryoglobulins, 
but do subsequently react with Clq, even at room 
temperature! 
For several years, we have been interested in 
how RF might modify IgG aggregates or immune 
complexes in human disease ( 11, 12). We have 
wondered whether RF might affect the deposition 
or metabolism of complexes by changing their size 
or their physicochemical properties in some other 
way. Small, soluble complexes might be made in-
soluble by RF; this might serve a protective function 
or a pathogenetic function depending on the circum-
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Fig. 3-Effect of lgM rheumatoid factor on bNA-anti-
DNA complexes. Constant amounts of IgM [either control 
(C) or containing rheumatoid factor (RF)] are added to 
constant amounts of anti-DNA (SLE) serum and increasing 
amounts of . DNA. Much more radioactive DNA is found 
in the precipitate when RF is added than in appropriate 
control systems. 
stances ( 13). Figure 3 shows that RF has the 
capability of precipitating partially soluble DNA-
anti-DNA complexes form!!d in vitro when one adds 
increasing amounts of ~abelled DNA to an SLE 
serum. It can be seen that much more precipitate 
is formed (based on counts of radioactive DNA in 
the precipitate) in the presence of RF than whert 
the complexes are formed in the presence of control-
lgM or buffer alone. We interpret these findings to 
mean that RF can interact with and precipitate 
DNA-anti-DNA complexes, thus converting these 
partially soluble complexes into insoluble complexes. 
As mentioned above, such a function for RF in vivo 
could be either protective or damagihg. 
Figure 4 shows effects of RF on cryoprecipitates. 
It would appear that RF has the potential for either 
increasing or decreasing cryoprecipitation, probably 
depending on characteristics of the cryoprecipitate. 
Conceivably one might be dealing with a system 
analagous to an antigen-antibody complex which 
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would precipitate at equivalence but would resohi-
bilize in both antigen and antibody excess. 
Table 5 shows the sort of data being accumu-
lated currently on patients seen at the University qf 
Virginia Lupus Clinic. In the serum of this patient 
before treatment, a Clq precipitin was found, along 
with 3+ cryoglobulins, strong anti~DNA activity, a 
low C level, and strong ANF staining: After institu-
tion of steroid treatment, the Clq precipitin dis-
appeared, but then we found material in the serum 
reacting with RF! (This often-seen reciprocal rela-
tion is of great interest to us, but we don't under-
stand it.) Cryoglobulins disappeared (as did the 
anti-DNA antibodies) and at the same time the 
serum C level returned to normal. Since starting 
treatment, the patient has done well, and we have 
continued to be on the lookout for. the reappearance 
of those factors associated with disease activity as 
we slowly lower the steroid dose. 
Table 6 is an analysis of serum material bound 
to Clq on a cyanogen bromide Sepharose® column. 
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Fig. 4-Effect of lgM rheumatoid factor on three SLE sera 
containing cryoglobulins. After addition of RF to fresh sera 
Sn and Wa, less cryoglobulin was detected after 48 hours 
at 4°C; when RF was added to serum Ca, however, more 
cryoprotein was detected. 
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TABLE 5 
S. P. (SLE) 
Complexes 
Clq RF Cr yo 
4/6/72 + 3+ 
Treatment Started 
4/ 11 / 72 + 
+ 
ND* 
4/ 13 /72 ND 
4/ 17 / 72 ND 
4/21/72 1-2+ 
5/ 2/ 72 
6/13/72 
7 / 25/ 72 
11 / 21 / 72 
* ND = Not Done 
One notes the presence in the two eluates of IgG 
and IgM but no anti-DNA or DNA. Currently, we are 
analyzing these eluates by a variety of techniques in-
cluding animal immunizations (to elicit antibodies to 
any infectious agents which might be there). Charac-
tedstics of Clq precipitins are also being compared 
with characteristics of cryoglobulins. It should be 
noted at this point that normal serum also contains 
significant amounts of material which bind to the 
Clq adsorbent. 
In summary, we can draw very few firm con-
clusions about immune complexes in patients with 
SLE. SLE patients during episodes of disease activity 
often show both cryoglobulins anq Clq precipitins 
in their sera, but in our experience, the sera may 
show only one of the factors and occasionally neither 
one is found. When cryoglobulins are removed from 
sera, Clq precipitins not only remain in the super-
natant but occasionally may be found in the super-
TABLE 6 
ANALYSIS OF ELUATES BOUND TO INSOLUBLE CIQ 
E.F. (SLE)* 
lgG (mg) 3. 12 
lgM (mg) 0 .49 
IgA (mg) 0 
Clq + 
DNA 
Anti-DNA 
RF 1:8 
Pptns. vs Clq + 
* SLE = Lupus serum eluate 
** N = Normal serum eluate 
J.D. (N)** 
0 .73 
0 . 31 
0 
Trace 
1 :8 
+ 
2+ 
Anti-DNA 
3+ 
3+ 
2-3+ 
2-3+ 
2+ 
ANF 
4+ 
ND 
ND 
ND 
1-2+ 
ND 
3+ 
3-4+ 
3-4+ 
CH50 
10 
13 
ND 
ND 
ND 
40 
53 
48 
45 
natant for the first time. This finding suggests that 
cryoglobulins and Clq precipitins are at least in part 
distinct. RF may interact with DNA-anti-DNA com-
plexes and cryoprecipitates at · least in vitro. Studies 
are in progress to furtfler characterize the material 
found in, the~e complexes. Hopefully, a particular 
antigen or a particular characteristic of SLE com-
plexes will be found which will lead to a better 
understanding of the primary cause and intermediate 
mechanisms involved in the serious disease kriown 
as SLE. 
REFERENCES 
1. ARA COMMITTEE OF DIAGNOSTIC AND THERAPEUTIC 
CRITERIA: Preliminary criteria for the classification of 
systemic lupus erythematosus. Bull R heum Dis 21:643, 
1971. 
2. GERMUTH FG JR: A comparative histologic and im-
munologic study in rabbits of induced hypersensitivity 
of the serum sickness type. J Exp Med 97:257, 1953. 
3. DIXON FJ : The role of antigen-antibody complexes in 
diseases. The Harvey Lectures, Series 58:21 , 1962-63. 
4. McINTOSH RM, GRoss M, LAPLANTE M , KAUFMAN DB, 
KuLvINSKAS C: Cryoproteins in immune complex dis-
ease: Role of nephrectomy and implications in recurrent 
glomerulonephritis in human transplants. Exp Med Surg 
29: 108, 1971. 
5. AGNELLO V, WINCHESTER RF, KUNKEL HG: Precipitin 
reactions of the Clq component of complement with 
aggregated y-globulin and immune complexes in gel 
diffusion. Immunology 19:909, 1970. 
70 
6. MOWBRAY JF, HOLBOROW EJ, HOFFBRAND AV, SEAH 
PP, FRY L: Circulating immune complexes in dermatitis 
herpetiformis. Lancet 1: 400, 1973. 
7. DOE WF, BOOTH CC, BROWN DL : Evidence for com-
plement-binding immune complexes in adult coeliac 
disease, Crohn's disease, and ulcerative colitis. Lancet 
1:402, l973. 
8. JEWELL DP, MACLENNAN ICM: Circulating immune 
complexes in inflammatory bowel disease. Clin Exp 
Immunol 14:219, 1973. 
9. FATHMAN CG: Characterization of circulating antigen-
antibody complexes in patients with systemic lupus 
erythematosus. Clin Res 21:577, 1973 (abstract). 
DAVIS: IMMUNE COMPLEX REACTIONS 
10. AGNELLO V, KOFFLER D, EISENBERG JW, WINCHESTER 
RJ, KUNKEL HG : Clq precipitins in the sera of patients 
with systemic lupus erythematosus and other hypocom-
plementemic states: Characterization of high and low 
molecular weight types. I Exp Med 134:2285, 1971. 
11. DAVIS JS, TORRIGIANI G: Effects of rheumatoid factor 
on in vivo distribution of aggregated human lgG and 
antigen-antibody complexes. Proc Soc Exp Biol Med 
125:772, 1967. 
12. GouGH WW, DAVIS JS: Effects of rheumatoid factor on 
complement levels in vivo. Arth Rheum 9 :555, 1966. 
13. DAVIS JS: A hypothetical common mechanism in sys-
temic lupus erythematosus and rheumatoid arthritis. 
Arth Rheum 9 :631 , 1966. 
